InterventionsHuman trial

Greater Combined A1C Reductions and Weight Loss with 25 mg and 50 mg vs. 14 mg Oral Semaglutide in Adults with T2D: Evidence from PIONEER PLUS

ADA Scientific Sessions 2026 Abstract

The paper

Jens Aberle, Paweł Bogdański, Erik Ising,

Chethana K. R, A.P. Jahagirdar,

Sue D. Pedersen

Hamburg

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Late-breaking 2835-LB

doi.org/10.2337/db26-2835-lb

Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026